Cargando…

Durability of Telbivudine-Associated Improvement of Renal Function Following Withdrawal or Switching of Antivirals in Chronic Hepatitis B Patients

BACKGROUND: Besides antiviral activities against hepatitis B virus (HBV), telbivudine has an extrahepatic pharmaceutical effect: to improve renal function assessed by estimated glomerular filtration rate (eGFR). However, the durability of this effect after withdrawal of telbivudine or switching to o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsu, Chao-Wei, Chen, Yi-Cheng, Chang, Ming-Ling, Lin, Chen-Chun, Lin, Shi-Ming, Chen, Wei-Ting, Chu, Yu-De, Yeh, Chau-Ting
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772403/ https://www.ncbi.nlm.nih.gov/pubmed/29362723 http://dx.doi.org/10.1093/ofid/ofx271

Ejemplares similares

Decrease of Serum Angiotensin Converting Enzyme Levels Upon Telbivudine Treatment for Chronic Hepatitis B Virus Infection and Negative Correlations Between the Enzyme Levels and Estimated Glumerular Filtration Rates
por: Liang, Kung-Hao, et al.
Publicado: (2014)

Renal Function Improvement by Telbivudine in Liver Transplant Recipients with Chronic Kidney Disease
por: Lee, Wei-Chen, et al.
Publicado: (2017)

Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections
por: Lin, Ming-Tsung, et al.
Publicado: (2013)

Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at Week 24
por: Hsu, Chao Wei, et al.
Publicado: (2012)

Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH)
por: Tsai, Pei-Chien, et al.
Publicado: (2020)

UGT2B28 genomic variation is associated with hepatitis B e-antigen seroconversion in response to antiviral therapy
por: Liang, Kung-Hao, et al.
Publicado: (2016)

Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals
por: Lin, Chuan-Pin, et al.
Publicado: (2021)

Predicting Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Receiving Finite Periods of Antiviral Therapy
por: Lin, Chih-Lang, et al.
Publicado: (2023)

Infant immune response to hepatitis B vaccine after fetal exposure to telbivudine
por: Li, Yandi, et al.
Publicado: (2022)

Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA
por: Kim, Dong Hyun, et al.
Publicado: (2017)

Effectiveness of telbivudine antiviral treatment in patients with hepatitis B virus-associated glomerulonephritis: A 104-week pilot study
por: Yan, Zhaoping, et al.
Publicado: (2018)

Durable Sustained Virologic Response After Oral Directly Acting Antiviral Therapy Despite Immunosuppressive Treatment
por: Hahn, Katherine J., et al.
Publicado: (2015)

The Efficacy of Add-on Telbivudine Versus Switching to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients With Poor Responses to Adefovir
por: Wei, Xin, et al.
Publicado: (2016)

Microelimination of Chronic Hepatitis C by Universal Screening Plus Direct-Acting Antivirals for Incarcerated Persons in Taiwan
por: Yang, Tsung-Hua, et al.
Publicado: (2020)

Case report: lactic acidosis and rhabdomyolysis during telbivudine and tenofovir treatment for chronic hepatitis B
por: Ying, Yue, et al.
Publicado: (2018)

Hepatitis C Virus Reinfection in People With HIV in Taiwan After Achieving Sustained Virologic Response With Antiviral Treatment: The RECUR Study
por: Liu, Chen-Hua, et al.
Publicado: (2022)

Safety and efficacy of telbivudine for the treatment of chronic hepatitis B
por: Osborn, Melissa K
Publicado: (2009)

Viral Interference Between Dengue Virus and Hepatitis C Virus Infections
por: Liang, Po-Cheng, et al.
Publicado: (2020)

On-treatment mortality predictors in chronic hepatitis B patients experiencing severe acute exacerbation: a prospective observational study
por: Chen, Yi-Cheng, et al.
Publicado: (2013)

Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection
por: Liu, Chen-Hua, et al.
Publicado: (2017)

Factors Related to Significant Improvement of Estimated Glomerular Filtration Rates in Chronic Hepatitis B Patients Receiving Telbivudine Therapy
por: Lin, Te-Fu, et al.
Publicado: (2017)

Comparison of telbivudine and entecavir on the change of off- treatment eGFR after 3 years of treatment in non-cirrhotic chronic hepatitis B patients
por: Lin, Yang-Sheng, et al.
Publicado: (2017)

Phenotypic and Genotypic Shifts in Hepatitis B Virus in Treatment-Naive Patients, Taiwan, 2008–2012
por: Yeh, Chau-Ting, et al.
Publicado: (2017)

Hepatitis B Virus Covalently Closed Circular DNA Predicts Postoperative Liver Cancer Metastasis Independent of Virological Suppression
por: Hsu, Chao-Wei, et al.
Publicado: (2021)

Telbivudine-Induced Myopathy: Clinical Features, Histopathological Characteristics, and Risk Factors
por: Lan, Min-Yu, et al.
Publicado: (2023)

Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B
por: Hou, Jin-Lin, et al.
Publicado: (2015)

Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review
por: Zhao, Shushan, et al.
Publicado: (2010)

Hepatic inflammation mediated by hepatitis C virus core protein is ameliorated by blocking complement activation
por: Chang, Ming-Ling, et al.
Publicado: (2009)

Comparison of the Efficacies and Safety of Combined Therapy between Telbivudine Plus Adefovir and Lamivudine Plus Adefovir in Patients with Hepatitis B Virus Infection in Real-World Practice
por: Lin, Ming-Tsung, et al.
Publicado: (2016)

Comparison of the efficacy and safety of tenofovir and telbivudine in interrupting mother-to-child transmission of hepatitis B virus
por: Zhu, Bo, et al.
Publicado: (2021)

Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B
por: Kim, Eun Hye, et al.
Publicado: (2013)

Kinetics of hepatitis B surface antigen and estimated glomerular filtration rate in telbivudine-treated hepatitis B patients with different rescue strategies
por: Yu, Hsien-Chung, et al.
Publicado: (2020)

Hepatitis B Vaccination Impact and the Unmet Need for Antiviral Treatment in Blantyre, Malawi( )
por: Stockdale, Alexander J, et al.
Publicado: (2021)

Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine
por: Cai, Shaohang, et al.
Publicado: (2017)

Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment
por: Liu, Chun Jen, et al.
Publicado: (2021)

Telbivudine can safely reduce mother-to-child transmission in chronic hepatitis B women after 12 weeks of gestation
por: Han, Li-fen, et al.
Publicado: (2019)

Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19
por: Chen, Jun, et al.
Publicado: (2020)

Telbivudine on IgG-associated hypergammaglobulinemia and TGF-β1 hyperactivity in hepatitis B virus-related liver cirrhosis
por: Ho, Cheng-Hsun, et al.
Publicado: (2019)

Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B
por: Yeh, Chau-Ting, et al.
Publicado: (2011)

Baseline Prognostic Factors and Statistic Model to Predict Early Virological Response in Telbivudine-Treated Patients With Chronic Hepatitis B
por: Zhou, Rui, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_o24ipfbf65u1tpk6q86pv4c7n9